RESULTS FROM WORK TO DEVELOP A PARSORTIX-BASED Her2 assay KIT SHOWCASED AT INTERNATIONAL LIQUID BIOPSY CONFERENCE ...

OS Therapies, Inc. ("OS Therapies" or "the Company"), a clinical-stage cancer immunotherapy and antibody drug conjugate biotechnology company, today reported financial results for the third quarter of ...

The Guildford, England-based liquid biopsy company is presenting the new test results at the American Association for Cancer Research's Special Conference, 'Liquid Biopsy: From Discovery to Clinical ...

The PIK3CA wild-type cohort of the Phase 3 VIKTORIA-1 trial is 100% enrolled; expect to report topline data for this cohort in late Q1 2025 or Q2 2025Approximately $264 million in cash, cash ...

Q3 2024 Earnings Call Transcript November 13, 2024 Operator: Good afternoon and welcome to Oncolytics Biotech’s Third Quarter 2024 Conference Call. All participants are in a listen-only mode. There ...

A woman whose cancer has spread to her bones, back, pelvis and neck but has been denied a life-extending drug because she ...

(Alliance News) - The following stocks are the leading risers and fallers on AIM on Friday.

According to a recent article in Biospace ,"The solid tumors market size reached a value of US$ 170.3 Billion in 2023. Looking forward, the market is expected to reach US$ 375.4 Billion by 2034, ...

Snow White star Rachel Zegler wished Americans who voted for Donald Trump 'never know peace' after his landslide election ...

Enliven Therapeutics (ELVN – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Sam ...

JonesTrading analyst Soumit Roy has maintained their bullish stance on ELVN stock, giving a Buy rating today. Soumit Roy has given his Buy ...

Q3 2024 Earnings Call Transcript November 14, 2024 Operator: Good afternoon, ladies and gentlemen, and welcome to the ...